AstraZeneca stock falls after FDA panel votes against new cancer drug
An FDA advisory panel voted against AstraZeneca's new cancer drug camizestrant, citing insufficient evidence that early treatment based on tumor detection improves long-term outcomes. While the drug showed a 56% reduction in disease progression or death in the SERENA-6 trial, panelists expressed concerns about altering standard therapy too soon. AstraZeneca maintains confidence in the drug and will continue working with the FDA, though the decision may impact investor sentiment.
- ▪The FDA panel voted against camizestrant based on the Phase 3 SERENA-6 trial, which showed a 56% reduction in risk of disease progression or death.
- ▪Panelists did not raise major safety concerns but questioned whether early intervention improves long-term patient outcomes.
- ▪AstraZeneca says it still believes in camizestrant and will continue collaborating with the FDA during its ongoing review.
- ▪Analysts note the SERENA-6 trial was a small part of AstraZeneca's $80 billion 2030 sales forecast and not central to its Buy thesis.
- ▪AstraZeneca recently reported strong Q1 results and has 11 upcoming data readouts expected in 2026.
Opening excerpt (first ~120 words) tap to expand
The vote was based on the Phase 3 results for the clinical trial SERENA-6 presented in 2025, which showed a 56% reduction in the risk of disease progression or death, compared to standard of care.While the vote outcome is negative for the near-term regulatory path, the debate is nuanced, said Barclays analyst James Gordon. The panel didn't dismiss the drug's efficacy or future potential, it simply concluded that the SERENA-6 trial didn't prove that acting on tumor detection before radiographic progression improves long-term outcome for patients, Gordon said.The panel didn't voice significant concern about the toxicity or overall safety of the drug. AstraZeneca said it would continue to work with the FDA as it completes its review of the application for camizestrant.
…
Excerpt limited to ~120 words for fair-use compliance. The full article is at CNBC — Top.
Discussion
0 commentsMore from CNBC — Top
